Key facts
- It has raised $47.2M; the latest was Later Stage VC in Sep 2025.
- Notable investors include CICC Capital, Beijing State-owned Capital Operation and Management, CMB International Capital, Tsinghua Capital, Hongtai Capital Holdings — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for CytoNiche
- ·The full record, as it builds
Funding rounds
No funding rounds for CytoNiche are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CytoNiche
Developer of 3D micro-structure engineering technology intended for stem cell research. The company specialises in the research of 3D cell tissue engineering for the development of high-quality stem cell cultures, injectable 3D micro-tissue treatment and 3D drug screening microcarriers used for extensive drug screening operations, providing reliable 3D micro-tissue products and services for research institutes, clinical institutions, stem cell companies and drug research enterprises.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Website
- cytoniche.com/
- Ownership
- Privately Held (backing)
CytoNiche doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CytoNiche shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CytoNiche in its N-PORT filings yet. We sweep new filings monthly.